Press releases

Press releases

26 January 2016  - Paris (France)

Ipsen announces publication in Pediatrics of the results of the phase III randomized study showing the efficacy and safety of Dysport® (abobotulinumtoxinA) in children with dynamic equinus foot deformity due to cerebral palsy

06 January 2016  - Paris (France)

Ipsen and Galderma expand current distribution agreement for Dysport® in aesthetic indications to some key Asia-Pacific territories

17 December 2015  - Paris (France)

Ipsen announces its corporate agenda for 2016

01 December 2015  - Paris (France)

Ipsen's partner Lexicon announced that Telotristat Etiprate had achieved positive top-line results in second phase 3 clinical trial

19 November 2015  - Paris (France)

Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology

29 October 2015  - Paris (France)

Ipsen: sales in the 3rd quarter and first nine months of 2015

28 October 2015  - Paris (France)

Telesta Therapeutics and Ipsen announce exclusive license agreement for MCNA for the treatment of non-muscle invasive bladder cancer in major ex-United States territories

26 October 2015  - Paris (France)

Ipsen and EpiVax collaborate to produce next generation botulinum toxins

22 October 2015  - Paris (France)

Ipsen presents additional results from a Phase III clinical trial of the investigational use of Dysport® in children with spastic equinus foot deformity due to cerebral palsy

19 October 2015  - Paris (France)

Ipsen’s partner Lexicon announced at the 2015 Neuroendocrine Tumor Society Annual Symposium (Austin, Texas) that telotristat etiprate was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study in cancer patients whose carcinoid syndrome was not adequately controlled by somatostatin analog (SSA) therapy.

Updated on 31 July 2015